33 results about "Drug rash" patented technology

The invention relates to a medicine for desensitizing, eliminating rashes and sores. The medicine for desensitizing, eliminating rashes and sores of the present invention is to take 20-40g of Radix Astragali, 20-40g of Radix Glycyrrhizae, 15-35g of Polygonum Polygoni Multiflori, 15-35g of Polygonatum Polygonatum, 10-20g of Morinda officinalis, and dry the traditional Chinese medicines of the above-mentioned parts by weight, Then grind it into a fine powder, add 100~200g of Vaseline, mix well, and prepare it. The medicine for desensitizing rashes and sores of the present invention is obtained through many years of clinical experience. It has a unique curative effect on chronic diseases, and the effect is better than western medicine, and it has been tried and tested.

The invention relates to a medicament, in particular to a medicament for treating rash, which is prepared from various traditional Chinese medicines serving as raw materials, and mainly solves the problem that the conventional medicament for treating rash has effect of curing symptoms but not root causes, causes recrudescence, has large side effects, is easy to generate medicament resistance, has poor curative effect and the like. The medicament consists of pseudoginseng root, figwort root, great burdock achene, dendrobium, coastal glehnia root, Chinese dwarf cherry seed, dwarf lilyturf tuber, fragrant solomonseal rhizome, bupleurum, baical skullcap root, Chinese gentian, natural indigo, talcpowder, asiatic moonseed rhizome, blackberrykiky rhizome, rehmannia, cortex moutan, green tangerine peel, cicada shell, hawthorn, stiff silkworm, Mongolian snakegourd root, indigowoad leaf, liquorice, Chinese date and ginger according to a certain ratio. The medicament is prepared from the traditional Chinese medicines to treat and condition the disease, treats both the symptoms and the root causes, and has the advantages of small side effect, no medicament resistance after long-term administration, no recrudescence, obvious curative effect and high cure rate.

The invention discloses traditional Chinese drug antipyretic pills, and relates to the technical field of traditional Chinese medicine. The traditional Chinese drug antipyretic pills provided by the present invention comprise the following raw materials, by weight, 1-50 parts of an extract of a component A, 1-50 parts of curcuma powder, 50-200 parts of cape jasmine powder and 50-200 parts of coptis chinensis powder, wherein the component A comprises the raw materials of pinus koraiensis branches, birch branches and poplar branches, wherein a weight ratio of the pinus koraiensis branches to the birch branches to the poplar branches is 1:1-4:1-4. The traditional Chinese drug antipyretic pills have effects of convulsion relieving and resuscitation, fever removing and heat clearing. In addition, after taking the traditional Chinese drug antipyretic pills, patients have good drug tolerance; gastrointestinal reactions are not generated; liver function indexes and kidney function indexes show no abnormal before and after taking the traditional Chinese drug antipyretic pills; anaphylactic responses such as erythra and the like are not generated; the traditional Chinese drug antipyretic pills have rapid onset and a short course of treatment.

The invention discloses an application of fraxinellone in preparation of drugs for treating allergic skin diseases. The allergic skin diseases comprise urticaria, eczema, contact dermatitis, atopic dermatitis, anaphylactoid purpura and drug rash. According to the invention, fraxinellone is used for treating immune globulin E (IgE)-mediated skin diseases for the first time, and fraxinellone can promote Th1 type cells to generate IFN-gamma. 25 mg/kg of fraxinellone is given to mice with passive skin allergy, degranulation of skin tissue mast cells is inhibited, and the inhibition rate reaches 34.01%. 50 mg/kg of fraxinellone is given to mice with passive skin allergy, and the degranulation inhibition rate of skin mast cells reaches 54.34%. 100 mg/kg of fraxinellone is given to mice with passive skin allergy, and the degranulation inhibition rate of skin mast cells reaches 62.5%.

The invention relates to a traditional Chinese medicine composition for externally applying to treat benign prostatic hyperplasia. The traditional Chinese medicine composition is prepared from the following medicinal raw materials by weight: 450-550g of angelica sinensis, 450-550g of sichuan lovage rhizome, 450-550g of flos carthami, 450-550g of peach kernels, 450-550g of astragalus membranaceus, 450-550g of salviae miltiorrhizae, 450-550g of curcuma aromatica, 450-550g of cortex moutan and 450-550g of honeysuckle. The traditional Chinese medicine composition provided by the invention is suitable for crowds of all age groups and free of any influence on crowds with background diseases. Although the traditional Chinese medicine composition is prepared from common traditional Chinese medicines, the effect is still remarkable if the traditional Chinese medicine composition is used in an insisted manner. Under the joint effect with infrared rays, the efficacy is absorbed by virtue of skin vessels and the composition can be directly acted on the prostate. The most major advantage of the traditional Chinese medicine composition is to reduce adverse reactions caused by long-term administration of the patient. Except for a small part of patients with rash itch, no other obvious side effects are available, and the clinical follow-up survey effective rate is over 98%.

The invention relates to a traditional Chinese herbal medicine qi-tonifying and blood-nourishing food additive and a preparation method thereof, and relates to a medicine preparation comprising traditional Chinese medicines. The invention aims to provide the traditional Chinese herbal medicine qi-tonifying and blood-nourishing food additive with quick response, high effective rate and no side effect during long-time use, and the preparation method thereof. The traditional Chinese herbal medicine qi-tonifying and blood-nourishing food additive comprises the following components in parts by mass: 3 to 7 parts of fructus schizandrae, 3 to 7 parts of radix polygoni multiflori, 2 to 6 parts of fructus ligustri lucidi, 4 to 8 parts of folium nelumbinis, 5 to 9 parts of walnuts, 3 to 7 parts of radix ginseng, 4 to 8 parts of rhizoma atractylodis macrocephaiae, 8 to 12 parts of radix astragali and 8 to 12 parts of donkey-hide gelatin. The traditional Chinese herbal medicine qi-tonifying and blood-nourishing food additive can be added into beverage, food, supplements or breeding feed for long-time use, and avoids side effects of fever, drug rash, nausea, diarrhea and the like.

The invention provides a biological agent formula for facilitating skin wound healing and a preparation method thereof. The biological agent is prepared from lithospermum, radix angelicae, sanguisorba officinalis, Chinese angelica, Astragalus membranaceus, Kochia scoparia, honeysuckle, Scutellaria baicalensis, tea oil and beeswax. The method comprises the following steps of A powdering and grinding, B, herbal medicine preparation and C storing. Compared with the prior art, the biological agent has the advantages of relieving heat and removing toxic materials, removing the necrotic tissue and promoting granulation, clearing away heat and toxic materials, cooling blood to relieve pain, and being used for eczema, dermatitis, drug rash, scalding, anabrosis and the like, has the flexible performance similar to that of the human skin, can keep the certain form and strength when wetted, promotes granulation growth and skin regeneration, accelerates healing, reduces scars, and is good in biocompatibility and easy to degrade.

The medicine for treating acute urticaria is oral liquid preparation prepared with eight kinds of Chinese medicinal materials, including long-noded pit viper, chrysanthemum, cicada slough, isatis root, ledebouriella root, etc. in certain proportion. The medicine of the present invention can cure urticaria radically, and has high curative effect, less toxic side effect, and low cost.

The invention discloses application of dendrophenol and a composition thereof in preparation of drugs for treating allergic dermatosis, and belongs to the technical field of new medical application of active component dendrophenol of traditional Chinese medicinal materials. In particular to application of dendrophenol in preparation of drugs for treating allergic skin diseases, and the allergic skin diseases comprise urticaria, eczema, contact dermatitis, atopic dermatitis, anaphylactoid purpura and drug rash. Animal test results show that the dendrophenol can inhibit inflammatory response, ear swelling and scratching times of a guinea pig allergic skin disease model induced by 2, 4-dinitrochlorobenzene, and reduce infiltration of eosinophilic granulocytes and mast cells at an affected part, so that the dendrophenol has the effects of resisting allergic reaction, diminishing swelling and relieving itching, and has a very good treatment effect on allergic skin diseases.

The invention discloses application of HLA-C*02:01:01 alleles in detection or evaluation of adverse drug reactions of efavirenz, and relates to the technical field of biological medicines. Specifically, the invention discloses application of a substance for detecting whether a person has HLA-C*02:01:01 alleles or not in preparation of a product for detecting or evaluating the risk that the person has adverse drug reactions responding to efavirenz. The invention provides marker genes, namely the HLA-C*02:01:01 alleles, which can be used for detecting or evaluating the occurrence risk of adverse drug reactions responding to efavirenz. By detecting whether the to-be-detected person carries the HLA-C*02:01:01 alleles or not, the high-risk person with efavirenz-induced drug rash can be screened; and the application is used for guiding clinical medication, so that occurrence of efavirenz-induced drug rash is reduced.

The invention discloses a drug rash patient management system, and the system comprises an information management system, an information acquisition system, an information storage unit and a display device. The information management system is used for uniformly deploying the information acquisition system, the information storage unit and the display device, and is used for calculating and processing each piece of information; the information acquisition system comprises an image acquisition unit and a character input unit, the character input unit inputs information of a patient, and an image system acquires two-dimensional code or rash image information; and the information storage unit is used for storing various information of the patient. According to the method for generating the nursing scheme for the patient with the drug rash, different nursing schemes are automatically generated, and various information of the patient is considered, so that exclusive nursing schemes can be generated according to different patients, the later nursing effect is better, and the time consumed by automatically generating the nursing schemes is shorter, so that medical staff can obtain a nursing scheme more quickly, and a large amount of time is saved.

The invention discloses a new application of an HLA-B* 13: 02 allele. The invention discloses an application of a substance for detecting an HLA-B* 13: 02 allele or a substance for detecting HLA-B* 13: 01 allele and the HLA-B* 13: 02 allele in preparation of a product for detecting or evaluating the adverse drug reaction risk of human responding to levofloxacin or the severe drug rash risk causedby levofloxacin. Experiments prove that alleles of human leukocyte antigen genes, namely HLA-B* 13: 01 and/or HLA-B* 13: 02, are related to severe drug rash risks caused by levofloxacin. HLA-B* 13: 01and/or HLA-B* 13: 02 alleles can be used as marker genes for predicting the occurrence risk of severe drug rash caused by levofloxacin.

The invention provides a medicine rash plasma exosome protein and a kit thereof, and relates to the technical field of kits. According to the kit for the medicine rash plasma exosome protein, a box body and a box cover, a limiting plate is fixedly arranged in the box body, a plurality of containing through grooves are formed in the limiting plate, positioning assemblies are arranged in the containing through grooves, a bearing plate is arranged at the bottom of the limiting plate, and bearing mechanisms are fixedly arranged at the positions, corresponding to the containing through grooves, of the bearing plate; the bearing mechanism comprises a fixing cylinder, a positioning assembly is also arranged in the fixing cylinder, and buffering sets are arranged at the positions, corresponding to the containing through grooves, of the box cover. According to the kit for the medicine rash plasma exosome protein, vibration energy from reagent bottles is absorbed through a plurality of elastic strips in the two positioning assemblies and a buffer assembly arranged at the bottom of the box cover in a matched mode, so that the reagent bottles are stably and neatly located in the box body, and the possibility that reagent liquid in the reagent bottles generates foam due to shaking is reduced.

The invention discloses application of a CCR4 receptor antagonist, particularly to application of a CCR4 receptor antagonist in preparation of medicine for treating drug rash. The CCR4 receptor antagonist has the better effect than prednisone acetate and has the quick effect, so that the pain of a patient is relieved more quickly. The CCR4 receptor antagonist has a quick effect especially on the eruption rash or urticaria type rash to alleviate the pain of the patient quickly. When the CCR4 receptor antagonist is AZD2098, the CCR4 receptor antagonist has a good curative effect on the drug rash, especially on the eruption rash; and when the CCR4 receptor antagonist is Compond22, the CCR4 receptor antagonist has a good curative effect on the drug rash, especially the urticaria type drug rash.